KVG, Cost-Con­tain­ment Mea­su­res – Packa­ge 2: Excep­ti­on to the Public Principle?

On August 19, 2020, the Fede­ral Coun­cil deci­ded to open the con­sul­ta­ti­on pro­ce­du­re on the second cost con­tain­ment packa­ge (indi­rect coun­ter-pro­po­sal to the “cost bra­ke initia­ti­ve”). The con­sul­ta­ti­on pro­ce­du­re will last until Novem­ber 19, 2020, in which it is pro­po­sed to crea­te the fol­lo­wing new Art. KVG to be created:

Art. 52c Excep­ti­on to the right of access to offi­ci­al documents

Access to offi­ci­al docu­ments pur­su­ant to Artic­le 5 of the Public Infor­ma­ti­on Act of 17 Decem­ber 200 shall be denied inso­far as they rela­te to the amount, cal­cu­la­ti­on or moda­li­ties of refunds pur­su­ant to Artic­le 52b.

The FDPIC has alre­a­dy oppo­sed this pro­po­sal tur­ned; it was “essen­ti­al that the public con­ti­n­ue to have the oppor­tu­ni­ty to under­stand the FOPH’s licen­sing practices.”

The Expl­ana­to­ry Report explains the pro­po­sed legis­la­ti­on as follows:

Access to infor­ma­ti­on on the amount, cal­cu­la­ti­on and moda­li­ties of refunds under Artic­le 52b should now be able to be denied. Exclu­ded from access are on the one hand, the amount of reim­bur­se­ment, i.e. the amount that the licen­see reim­bur­ses to the insurer or the fund for reim­bur­se­ments. On the other hand, access to the cal­cu­la­ti­on of reim­bur­se­ments is also exclu­ded. This also affects the deri­va­ti­on as well as the deter­mi­na­ti­on of reim­bur­se­ments. In this con­text In par­ti­cu­lar, access to the assess­ment of cost-effec­ti­ve­ness or the two pri­cing cri­te­ria (for­eign pri­ce com­pa­ri­son and the­ra­peu­tic cross-com­pa­ri­son) be exclu­ded. It must not be pos­si­ble to infer the spe­ci­fic amount of the refund. Final­ly, access to infor­ma­ti­on regar­ding moda­li­ties in con­nec­tion with the refund is denied. The scope of appli­ca­ti­on of Artic­le 52c depends on how the Fede­ral Coun­cil spe­ci­fi­es and con­cre­ti­zes Artic­le 52b at ordi­nan­ce level.

This pro­po­sal is par­ti­cu­lar­ly wel­co­me as a signal that the prin­ci­ple of public access is gene­ral­ly being overs­t­ret­ched. This is par­ti­cu­lar­ly true with regard to the pro­tec­tion of com­pa­nies’ trade secrets, which are inter­pre­ted very narrowly.

Aut­ho­ri­ty

Area

Topics

Rela­ted articles

Sub­scri­be